Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia

INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Int J Infect Dis
المؤلفون الرئيسيون: Górgolas Hernández-Mora, Miguel, Cabello Úbeda, Alfonso, Prieto-Pérez, Laura, Villar Álvarez, Felipe, Álvarez Álvarez, Beatriz, Rodríguez Nieto, María Jesús, Carrillo Acosta, Irene, Fernández Ormaechea, Itziar, Al-Hayani, Aws Waleed Mohammed, Carballosa, Pilar, Calpena Martínez, Silvia, Ezzine, Farah, Castellanos González, Marina, Naya, Alba, López De Las Heras, Marta, Rodríguez Guzmán, Marcel José, Cordero Guijarro, Ana, Broncano Lavado, Antonio, Macías Valcayo, Alicia, Martín García, Marta, Bécares Martínez, Javier, Fernández Roblas, Ricardo, Piris Pinilla, Miguel Ángel, Fortes Alen, José, Sánchez Pernaute, Olga, Romero Bueno, Fredeswinda, Heili-Frades, Sarah, Peces-Barba Romero, Germán
التنسيق: Artigo
اللغة:Inglês
منشور في: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585732/
https://ncbi.nlm.nih.gov/pubmed/33115682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.10.045
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة